The integration of sophisticated pharmacological agents with circuit‐level neuromodulation represents the next frontier in treating cholinergic dysfunction across the spectrum of neurodegenerative disorders, advancing the therapeutic goal from chemical enhancement to circuit repair and regeneration.
Abstract
ABSTRACT Background The central cholinergic system has long been a cornerstone therapeutic target for neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB). For decades, acetylcholinesterase inhibitors (AChEIs) have served as the standard symptomatic treatment, providing cognitive and functional relief by enhancing synaptic acetylcholine levels. However, their limited efficacy and inability to modify disease progression underscore the fundamental constraint of purely neurochemical enhancement, especially in the context of progressive cholinergic neuron loss. Results and Conclusion This review critically examines the evolution of cholinergic therapies beyond AChEIs. We first explore the shift from broad neurotransmitter enhancement toward precision targeting of receptor subtypes and the development of multi‐target pharmacological strategies. Furthermore, we highlight how neuromodulation techniques—including vagus nerve stimulation, deep brain stimulation, and non‐invasive brain stimulation—directly engage and restore dysfunctional neural circuits, moving beyond mere chemical enhancement. Emerging directions such as advanced cholinergic imaging, gene therapy, and cell‐based regeneration are also discussed as promising pathways toward true disease modification. Ultimately, the integration of sophisticated pharmacological agents with circuit‐level neuromodulation represents the next frontier in treating cholinergic dysfunction across the spectrum of neurodegenerative disorders, advancing the therapeutic goal from chemical enhancement to circuit repair and regeneration.
Alzheimer’s Disease (AD) is a neurodegenerative disorder with
progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress,
and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by
the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...
Nisha, Sumairah Qadir· Current Pharmaceutical Resea...· 0 citations
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, primarily caused by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain". Current therapeutic strategies focus on symptomatic relief, with acetylcholinesterase (AChE) i...
Sushma, Rishab Dubey, Rupa Chaturvedi et al.· Journal of Health Synapse· 0 citations
Synaptic plasticity refers to the fundamental process through which synaptic connections become stronger or weaker in response to experience, thereby forming the basis of learning and memory. Disruption of this process is increasingly regarded as a common underlying mechanism of several cognitive and neuropsychiatric d...
Alzheimer's Disease (AD) is a complex disorder whose underlying biology is not fully explained by traditional single-pathway models. For several decades, research has largely focused on the roles of amyloid-β and tau in the formation and deposition of plaques and neurofibrillary tangles associated with AD pathology and...
Desh Deepak Singh· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.